Dr Tim Mitchell

Sareum Ltd
Sareum Ltd

Position: CEO
Personal home page: http://www.sareum.co.uk

PubMed journal articles - click here

Research description

Sareum is a drug discovery and development company delivering targeted small molecule therapeutics, primarily focusing on cancer.
Sareum works with collaborators that include the Cancer Research Technology Pioneer Fund plus a world-wide network of research providers. Its research pipeline includes a CHK1 kinase programme, developed in collaboration with CRT, the Institute of Cancer Research and the CRT Pioneer Fund. This programme will start Phase 1 clinical trials at the Royal Marsden Hospital in June 2016.
SKIL® (Sareum Kinase Inhibitor Library) is Sareum's drug discovery technology platform that has so far produced the Company's Aurora+FLT3, Aurora+ALK, VEGFR-3, FLT3 & TYK2 kinase cancer and autoimmune disease research programmes. SKIL® can also generate drug research programmes against other kinase targets.

Research Programme
Onco-Innovation
Methods and technologies
Computational modelling
X-ray crystallography
Tumour type interests
Breast
Cervix
Colorectal
Leukemia
Lung
Ovary
Pancreas
Other
Keywords
kinase inhibitors
medicinal chemistry
molecular design
checkpoint kinase
FLT3 kinase
TYK2 kinase
Aurora kinase

Key publications

Multi-parameter lead optimization to give an oral checkpoint kinase 1 (CHK1) inhibitor clinical candidate: (R)-5-((4-((morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737). JD Osborne, TP Matthews, T McHardy, N Proisy, K-M J Cheung, M Lainchbury, N Brown, MI Walton, PD Eve, KJ Boxall, A Hayes, AT Henley, MR Valenti, AK De Haven Brandon, G Box, Y Jamin, SP Robinson, IM Westwood, RLM van Montfort, PM Leonard, MBAC Lamers, JC Reader, GW Aherne, FI Raynaud, SA Eccles, MD Garrett and I Collins, J. Med. Chem. 2016, Just Accepted Manuscript DOI: 10.1021/acs.jmedchem.5b01938

The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eµ-MYC driven B-cell lymphoma. MI Walton, PD Eve, A Hayes, AT Henley, MR Valenti, AK De Haven Brandon, G Box, KJ Boxall, M Tall, K Swales, TP Matthews, T McHardy, M Lainchbury, J Osborne, JE Hunter, ND Perkins, GW Aherne, JC Reader, FI Raynaud, SA Eccles, I Collins and MD Garrett, Oncotarget 2015, 7(3) 2329-2342

Using X-ray crystallography and molecular modelling to guide the design of small molecule kinase inhibitors